Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07527195) titled 'Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)' on April 7.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Novo Nordisk A/S
Condition:
Obesity
Intervention:
Drug: Cagrilintide
Drug: Semaglutide
Drug: Placebo cagrilintide
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: April 10, 2026
Target Sample Size: 100
Cou...